BLINDED BEVACIZUMAB

Blinded Bevacizumab Adverse Events Reported to the FDA Over Time

How are Blinded Bevacizumab adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Blinded Bevacizumab, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Blinded Bevacizumab is flagged as the suspect drug causing the adverse event.

Most Common Blinded Bevacizumab Adverse Events Reported to the FDA

What are the most common Blinded Bevacizumab adverse events reported to the FDA?

Febrile Neutropenia	262 (11.58%)
Pyrexia	51 (2.25%)
Dehydration	49 (2.17%)
Diarrhoea	46 (2.03%)
Neutropenia	44 (1.94%)
Pneumonia	37 (1.63%)
Convulsion	34 (1.5%)
Pulmonary Embolism	34 (1.5%)
Septic Shock	30 (1.33%)
Renal Failure Acute	28 (1.24%)
Mucosal Inflammation	26 (1.15%)
	Show More
Anaemia	25 (1.1%)
Haemoglobin Decreased	25 (1.1%)
Respiratory Failure	24 (1.06%)
Dyspnoea	23 (1.02%)
Blood Sodium Decreased	21 (.93%)
Gastric Perforation	21 (.93%)
Fatigue	20 (.88%)
Hypokalaemia	20 (.88%)
Pancytopenia	20 (.88%)
Platelet Count Decreased	18 (.8%)
Nausea	17 (.75%)
Sepsis	17 (.75%)
Vomiting	17 (.75%)
White Blood Cell Count Decreased	17 (.75%)
Ascites	16 (.71%)
Confusional State	16 (.71%)
Abdominal Pain	15 (.66%)
Death	15 (.66%)
Gastrointestinal Haemorrhage	15 (.66%)
General Physical Health Deteriorati...	15 (.66%)
Leukopenia	15 (.66%)
Lymphopenia	15 (.66%)
Rectal Ulcer	15 (.66%)
Haematochezia	14 (.62%)
Cerebral Ischaemia	13 (.57%)
Upper Gastrointestinal Haemorrhage	13 (.57%)
Asthenia	12 (.53%)
Ejection Fraction Decreased	12 (.53%)
Peritonitis	12 (.53%)
Atrial Fibrillation	11 (.49%)
Disease Progression	11 (.49%)
Neutropenic Sepsis	11 (.49%)
Stomatitis	11 (.49%)
Deep Vein Thrombosis	10 (.44%)
Hyponatraemia	10 (.44%)
Infection	10 (.44%)
Blood Creatinine Increased	9 (.4%)
Lower Limb Fracture	9 (.4%)
Mental Status Changes	9 (.4%)
Pneumonia Aspiration	9 (.4%)
Thrombocytopenia	9 (.4%)
Acute Respiratory Distress Syndrome	8 (.35%)
Alanine Aminotransferase Increased	8 (.35%)
Blood Potassium Increased	8 (.35%)
Cerebral Haemorrhage	8 (.35%)
Chest Pain	8 (.35%)
Malignant Neoplasm Progression	8 (.35%)
Pleural Effusion	8 (.35%)
Pneumothorax	8 (.35%)
Small Intestinal Obstruction	8 (.35%)
Splenic Abscess	8 (.35%)
Anorexia	7 (.31%)
Blood Urea Increased	7 (.31%)
Cardiac Failure	7 (.31%)
Cerebral Infarction	7 (.31%)
Cerebrovascular Accident	7 (.31%)
Decreased Appetite	7 (.31%)
Headache	7 (.31%)
Hyperglycaemia	7 (.31%)
Hypotension	7 (.31%)
Intestinal Obstruction	7 (.31%)
Laboratory Test Abnormal	7 (.31%)
Lethargy	7 (.31%)
Malaise	7 (.31%)
Muscular Weakness	7 (.31%)
Neutropenic Infection	7 (.31%)
Peripheral Sensory Neuropathy	7 (.31%)
Pneumonitis	7 (.31%)
Aspartate Aminotransferase Increase...	6 (.27%)
Colitis	6 (.27%)
Cystitis	6 (.27%)
Hypovolaemic Shock	6 (.27%)
Ileus	6 (.27%)
Neutrophil Count Decreased	6 (.27%)
Partial Seizures	6 (.27%)
Renal Failure	6 (.27%)
Somnolence	6 (.27%)
Sudden Death	6 (.27%)
Angina Pectoris	5 (.22%)
Blood Lactic Acid Increased	5 (.22%)
Constipation	5 (.22%)
Cough	5 (.22%)
Haemoptysis	5 (.22%)
Hepatic Artery Thrombosis	5 (.22%)
Hyperkalaemia	5 (.22%)
Metastases To Meninges	5 (.22%)
Multi-organ Failure	5 (.22%)
Oedema Peripheral	5 (.22%)
Opportunistic Infection	5 (.22%)
Oral Candidiasis	5 (.22%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Blinded Bevacizumab, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Blinded Bevacizumab is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Blinded Bevacizumab

What are the most common Blinded Bevacizumab adverse events reported to the FDA?

White Blood Cell	336 (14.85%)
Infections - Pathogen Unspecified	179 (7.91%)
Electrolyte And Fluid Balance Condi...	87 (3.84%)
Hematology Investigations	85 (3.76%)
Respiratory	79 (3.49%)
Gastrointestinal Signs	57 (2.52%)
Gastrointestinal Hemorrhages	54 (2.39%)
Gastrointestinal Ulceration And Per...	54 (2.39%)
Gastrointestinal Motility And Defec...	53 (2.34%)
Body Temperature Conditions	51 (2.25%)
Anemias Nonhemolytic And Marrow Dep...	47 (2.08%)
	Show More
Renal Disorders	47 (2.08%)
Central Nervous System Vascular	45 (1.99%)
Seizures	41 (1.81%)
Lower Respiratory Tract Disorders	40 (1.77%)
Neurological	40 (1.77%)
Water, Electrolyte And Mineral	37 (1.63%)
Pulmonary Vascular	35 (1.55%)
Gastrointestinal Stenosis And Obstr...	29 (1.28%)
Hepatic And Hepatobiliary	29 (1.28%)
Cardiac Arrhythmias	28 (1.24%)
Peritoneal And Retroperitoneal Cond...	28 (1.24%)
Cardiac And Vascular Investigations	23 (1.02%)
Fatal Outcomes	21 (.93%)
Pleural	20 (.88%)
Fungal Infectious	19 (.84%)
Hepatobiliary	19 (.84%)
Renal And Urinary Tract Investigati...	18 (.8%)
Deliria	17 (.75%)
Embolism And Thrombosis	17 (.75%)
Heart Failures	17 (.75%)
Appetite And General Nutritional	16 (.71%)
Decreased And Nonspecific Blood Pre...	16 (.71%)
Oral Soft Tissue Conditions	16 (.71%)
Bacterial Infectious	15 (.66%)
Gastrointestinal Inflammatory Condi...	15 (.66%)
Myocardial	15 (.66%)
Spleen, Lymphatic And Reticulendoth...	14 (.62%)
Coronary Artery	13 (.57%)
Glucose Metabolism Disorders	13 (.57%)
Miscellaneous And Site Unspecified ...	13 (.57%)
Urinary Tract Signs	13 (.57%)
Bone And Joint Injuries	11 (.49%)
Injuries	11 (.49%)
Investigations, Imaging And Histopa...	11 (.49%)
Metastases	11 (.49%)
Muscle	10 (.44%)
Peripheral Neuropathies	9 (.4%)
Platelet	9 (.4%)
Psychiatric	9 (.4%)
Cranial Nerve Disorders	8 (.35%)
Metabolic, Nutritional And Blood Ga...	8 (.35%)
Microbiology And Serology	8 (.35%)
Neoplasm Related Morbidities	8 (.35%)
Viral Infectious	8 (.35%)
Gastrointestinal Conditions	7 (.31%)
Headaches	7 (.31%)
Physical Examination Topics	7 (.31%)
Cardiac Valve	6 (.27%)
Encephalopathies	6 (.27%)
Epidermal And Dermal Conditions	6 (.27%)
Joint	6 (.27%)
Procedural And Device Related Injur...	6 (.27%)
Protein And Chemistry Analyses	6 (.27%)
Bone Disorders	5 (.22%)
Cardiac Disorder Signs	5 (.22%)
Leukemias	5 (.22%)
Mental Impairment	5 (.22%)
Musculoskeletal And Connective Tiss...	5 (.22%)
Pericardial	5 (.22%)
Depressed Mood Disorders	4 (.18%)
Gastrointestinal Vascular Condition...	4 (.18%)
Nervous System Neoplasms Malignant ...	4 (.18%)
Salivary Gland Conditions	4 (.18%)
Tissue	4 (.18%)
Anxiety Disorders	3 (.13%)
Breast Neoplasms Malignant And Unsp...	3 (.13%)
Chemical Injury And Poisoning	3 (.13%)
Coagulopathies And Bleeding Diathes...	3 (.13%)
Enzyme	3 (.13%)
Exocrine Pancreas Conditions	3 (.13%)
Inner Ear And Viiith Cranial Nerve	3 (.13%)
Movement Disorders	3 (.13%)
Skin And Subcutaneous Tissue	3 (.13%)
Synovial And Bursal	3 (.13%)
Therapeutic And Nontherapeutic Effe...	3 (.13%)
Thoracic Disorders	3 (.13%)
Upper Respiratory Tract Disorders	3 (.13%)
Vascular Hypertensive	3 (.13%)
Vision	3 (.13%)
Acid-base	2 (.09%)
Administration Site Reactions	2 (.09%)
Arteriosclerosis, Stenosis, Vascula...	2 (.09%)
Bone And Joint Therapeutic Procedur...	2 (.09%)
Endocrine Neoplasms Malignant And U...	2 (.09%)
Gallbladder	2 (.09%)
Gastrointestinal Neoplasms Malignan...	2 (.09%)
Hematological And Lymphoid Tissue T...	2 (.09%)
Increased Intracranial Pressure And...	2 (.09%)
Nephropathies	2 (.09%)
Respiratory And Pulmonary Investiga...	2 (.09%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Blinded Bevacizumab, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Blinded Bevacizumab is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.